Adherence of People Living with HIV to Tenofovir, Lamivudine, and Dolutegravir treatment and its associated factors

Not Applicable

Conditions: Health Condition 1: B20- Human immunodeficiency virus [HIV]disease

Recruitment & Eligibility

Inclusion Criteria

1) Patients above the age of 18 years

2) Patients diagnosed with HIV

3) PLHIV registered at ART Centre in Government Medical College and Rajindra Hospital, Patiala

4) Treatment naïve PLHIV initiated on Tenofovir 300 mg, Lamivudine 300 mg, Dolutegravir 50 mg, fixed-dose combination regimen

5) PLHIV on TLD with a minimum of 2 drug refills irrespective of follow-up period

Exclusion Criteria

1) Records with incomplete data on ART adherence

2) PLHIV not on Tenofovir 300 mg, Lamivudine 300 mg, Dolutegravir 50 mg, fixed-dose combination regimen

3) PLHIV whose ART regimen was switched during the study period

Primary Outcome Measures

Name	Time	Method
1) Adherence rate in people living with HIV on Tenofovir, Lamivudine, and Dolutegravir regimen. <br/ ><br> <br/ ><br>2) Factors associated with adherence in people living with HIV on Tenofovir, Lamivudine, and Dolutegravir regimen. <br/ ><br>Timepoint: Medical records for all patients put on anti-retroviral therapy fulfilling the inclusion and exclusion criteria will be reviewed on a retrospective basis for a duration of three consecutive months. <br/ ><br> <br/ ><br>All visits that the patient has completed within a period of one year from date of initiation of ART will be considered.

Secondary Outcome Measures

Name	Time	Method
1) Adherence between different age groups in people living with HIV on Tenofovir, Lamivudine, and Dolutegravir regimen. <br/ ><br> <br/ ><br>2) Adherence between gender in people living with HIV on Tenofovir, Lamivudine, and Dolutegravir regimen. <br/ ><br> <br/ ><br>3) Adherence between socio-economic classes in people living with HIV on Tenofovir, Lamivudine, and Dolutegravir regimen. <br/ ><br> <br/ ><br>4) Adherence between WHO Clinical Stages in people living with HIV on Tenofovir, Lamivudine, and Dolutegravir regimen.Timepoint: Medical records for all patients put on anti-retroviral therapy fulfilling the inclusion and exclusion criteria will be reviewed on a retrospective basis for a duration of three consecutive months. <br/ ><br> <br/ ><br>All visits that the patient has completed within a period of one year from date of initiation of ART will be considered.